Barr Pharmaceuticals

From SourceWatch
Jump to: navigation, search

Barr Pharmaceuticals, Inc. "are focused on developing, manufacturing and marketing quality generic and proprietary pharmaceuticals in specific therapeutic categories that generate sustainable profitability." [1]

"Barr Pharmaceuticals, Inc. is a Delaware holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. The Company’s generic products are marketed under the “Barr” label, and proprietary products are marketed under the “Duramed” label.

"For the fiscal year ended June 30, 2006, the Company recorded net earnings of $337 million on revenues of $1.3 billion. Of the $1.3 billion of revenues in fiscal 2006, $839 million were from sales of generic products, $330 million were from sales of proprietary products, and $146 million were attributed to revenues derived from co-promotion alliances, development agreements and other sources." [2]

Use of Video News Releases

In November 2006, the Center for Media and Democracy revealed that Barr Pharmaceuticals was one of the companies that used video news releases to advertise its product, though in the guise of news. [3][4]

Barr Directors (2005) [5]

Contact

Web: http://www.barrlabs.com

Resources and articles

Related Sourcewatch

References

  1. Mission, Barr Pharmaceuticals, accessed December 10, 2007.
  2. Corporate Profile, Barr Pharmaceuticals, accessed December 10, 2007.
  3. Dan Price, ""The Morning-After Shills: Stations Air Pharmaceutical Company VNR Without Attribution", PR Watch, November 14, 2006.
  4. Dan Price, ""I Want a New (Birth Control) Drug: KYW-3 Helps Push Brand-Name Pills", PR Watch, November 14, 2006.
  5. 2005 Annual Report, Barr Pharmaceuticals, accessed December 10, 2007.